About
About Shandong Wohua Pharmaceutical Co., Ltd
Shandong Wohua Pharmaceutical Co., Ltd. manufactures and sells pharmaceutical products in China. The company produces and sells tablets, granules, capsules, oral liquid, and pills; medicinal herb cultivation; and provides pharmaceutical technology consulting services. It also offers products including drugs for cardiovascular, cerebrovascular, and nervous system diseases, such as Wohua Xinkeshu tablets, Hedan tablets and capsules, Naoxueshu and Shenzhiling oral liquid, and Tongluo Huatan capsules; and drugs for musculoskeletal disorders, including Gusukang capsules/granules and Yidu Hanbi liquid; Yidu cold-rheumatism medicinal wine ingredients; brain blood circulation oral solution; Amber stone granules for urinary system diseases; Children's antipyretic granules for pediatric medication; Anti-itching granules for skin diseases; and Bile grass capsule for digestive and gynecological diseases, as well as Silkworm Nourishing Blood and Benefiting Kidney Granules for gynecological medication. In addition, the company offers Amber Xiaoshi granules, and Siyu Yangxue Yishen granules; Yanreqing granules, Antiviral oral liquid, and Niuhuang Yijin tablets for the treatment of dry throat and sore throat; Yinhuang granules for the treatment of wind-heat colds; Tongxuan Lifei pills for the treatment of wind-cold colds; Fangfeng Tongsheng pills for colds on the surface and heat inside; Huoxiang Zhengqi Water for the treatment of summer-heat colds; Shenling Baizhu, Buzhong Yiqi, and Xiangsha Liujun pills for the treatment of physical weakness colds; and Juhong Li Gao for the treatment of dry coughs with little sputum. The company was founded in 2003 and is based in Weifang, China. Shandong Wohua Pharmaceutical Co., Ltd. operates as a subsidiary of Beijing Zhongzheng Wanrong Investment(Group) Co., Ltd.
Visit company website
5 years, 5 months ago
Shandong Wohua Pharmaceutical Co., Ltd is currently in a long term downtrend where the price is trading 6.0% below its 200 day moving average.
From a valuation standpoint, the stock is 51.2% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 4.7.
Shandong Wohua Pharmaceutical Co., Ltd's total revenue rose by 15.8% to $252M since the same quarter in the previous year.
Its net income has increased by 15.2% to $51M since the same quarter in the previous year.
Finally, its free cash flow grew by 62.7% to $74M since the same quarter in the previous year.
Based on the above factors, Shandong Wohua Pharmaceutical Co., Ltd gets an overall score of 4/5.